Observational Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Feb 14, 2015; 21(6): 1907-1914
Published online Feb 14, 2015. doi: 10.3748/wjg.v21.i6.1907
Table 1 Background disposition and clinical characteristics n (%)
ParameterCasesControlsP valueOR (95%CI)
Gender0.192.0 (0.70-5.70)
Male15 (50)10 (33.3)
Female15 (50)20 (66.6)
Type of IBD0.450.56 (0.12-2.57)
CD25 (83.3)27 (90.0)
UC5 (16.7)3 (10.0)
Duration of IFX therapy1 (mo)21 ± 25.120.75 ± 25.50.97
Concomitant therapy11 (36.7)11 (36.7)1.001.00 (0.35-2.86)
Episodic therapy6 (20)6 (20.0)1.001.00 (0.28-3.54)
Median age (yr)33 ± 15.228.5 ± 10.70.24
Median disease duration (yr)10.5 ± 99 ± 7.70.65
Median age at diagnosis (yr)22 ± 12.420 ± 9.70.19
CD - disease location
Ileal9 (36)8 (29.7)0.621.30 (0.41-4.30)
Ileo-colonic8 (32)11 (40.7)0.510.68 (0.22-2.10)
Colonic8 (32)8 (29.6)0.851.10 (0.34-3.63)
CD - upper GI involvement2 (8)2 (7.4)0.931.08 (0.14-8.40)
CD - anal/perianal involvement13 (52)14 (51.8)0.991.00 (0.34-3.00)
CD - disease behavior
Non stricturing non penetrating12 (48)12 (44.5)0.791.15 (0.38-3.43)
Stricturing8 (32)10 (37.0)0.700.80 (0.25-2.50)
Penetrating5 (20)5 (18.5)0.891.10 (0.28-4.40)
UC - disease location
Proctitis00
Left-sided colitis2 (40)1 (33.3)
Extensive colitis3 (60)2 (66.7)
Extra-intestinal manifestations15 (50)15 (50.0)1.001.00 (0.36-2.75)
Smoking2 (6.7)5 (16.7)0.240.30 (0.06-2.00)
Immunomodulator therapy prior to infliximab therapy26 (86.7)23 (76.7)0.321.97 (0.51-7.63)
Adalimumab therapy prior to infliximab therapy4 (13.3)00.1210.30 (0.53-201.00)
Surgery prior to infliximab therapy8 (26.7)7 (23.3)0.761.19 (0.37-3.85)